MedPath

Phase II clinical study on combination of oxaliplatin (L-OHP) and S-1 in advanced / recurrent gastric cancer untreated with chemotherapy

Phase 2
Conditions
Gastric cancer
Registration Number
JPRN-jRCT2080220365
Lead Sponsor
Yakult Honsha Co.,Ltd.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Gastric cancer confirmed by histological diagnosis or cytologic diagnosis
- Unresectable advanced / recurrent gastric cancer
- Age of 20 years or older
- Not pretreated with chemotherapy drugs, immunotherapeutic drugs, or radiation therapy
- ECOG Performance Status 0 to 2

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Response Rate
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath